To evaluate the effectiveness of this approach, the authors used a preclinical model of TNBC, treating tumor-bearing mice with TNBC neoantigens and oncolytic VV, and assessed the impact on the induction of neoantigen-specific CD8+ T cells, tumor growth, and survival. The gene discussed is CD8A; the disease is neoplasm.